Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

In the randomized phase 2 NeoCOAST-2 platform trial in stage IIA-IIIB resectable NSCLC, a tumor-agnostic assay was used to assess ctDNA clearance at neoadjuvant cycle 3 day 1. Clearance was associated with longer event-free survival than non-clearance (pooled HR 0.22, 95% CI 0.11-0.45), and patients with both clearance and pathologic complete response had more favorable event-free survival than those with neither (HR 0.10, 95% CI 0.02-0.42).

NaturePubMed 42927884DOI 10.1038/s41586-026-11328-3